Kuangli Bio-Tech Holdings Co., Ltd. (TPE:6431)

Kuangli Bio-Tech Holdings Revenue

Kuangli Bio-Tech Holdings had revenue of 96.02M TWD in the quarter ending June 30, 2026, with 11.71% growth. This brings the company's total for the last twelve months to 363.27M, down -14.57% year-over-year. In the year 2025, Kuangli Bio-Tech Holdings had annual revenue of 377.03M, down -1.12%. That makes Kuangli Bio-Tech Holdings the 36,845th largest company in the world by revenue and 1,931st in Taiwan.

• Revenue (ttm): 363.27M
• Revenue Growth: -14.57%
• P/S Ratio: 4.05
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.47B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Biotechnology Segment 335.13M 88.9%
• Health Management Department 41.90M 11.1%

By Geography

Chart

• Mainland China 335.13M 88.9%
• Taiwan 41.90M 11.1%

Fiscal year ended Dec 31, 2025 See the full Kuangli Bio-Tech Holdings breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	377.03M	-4.27M	-1.12%
Dec 31, 2024	381.30M	87.93M	29.97%
Dec 31, 2023	293.37M	-48.79M	-14.26%
Dec 31, 2022	342.16M	9.53M	2.86%
Dec 31, 2021	332.63M	245.66M	282.47%

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 27, 2026

Data Sources Report a data error